GlucoTrack (NASDAQ:GCTK – Get Free Report) and Koninklijke Philips (NYSE:PHG – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Risk & Volatility
GlucoTrack has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Koninklijke Philips has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for GlucoTrack and Koninklijke Philips, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GlucoTrack | 1 | 0 | 0 | 0 | 1.00 |
| Koninklijke Philips | 1 | 3 | 0 | 0 | 1.75 |
Institutional & Insider Ownership
Valuation & Earnings
This table compares GlucoTrack and Koninklijke Philips”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GlucoTrack | N/A | N/A | -$19.39 million | ($18.04) | -0.03 |
| Koninklijke Philips | $20.17 billion | 1.31 | $1.01 billion | $1.17 | 23.02 |
Koninklijke Philips has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GlucoTrack and Koninklijke Philips’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GlucoTrack | N/A | -581.98% | -220.10% |
| Koninklijke Philips | 5.49% | 13.51% | 5.48% |
Summary
Koninklijke Philips beats GlucoTrack on 9 of the 11 factors compared between the two stocks.
About GlucoTrack
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease. In addition, the company offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. Further, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. The company has strategic partnership agreements with TriHealth, Northwell, and Atrium Health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
